Skip to content
2000
Volume 13, Issue 11
  • ISSN: 1389-5575
  • E-ISSN: 1875-5607

Abstract

Irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) are highly prevalent gastrointestinal disorders. Traditional symptoms based therapies had somewhat limited success and efficacy in addressing the disorders. Recently,linaclotide emerged as novel peptide capable of improving abdominal symptoms in patients suffering from IBS-C and CIC. Guanylate cyclase C (GC-C) receptor a multi domain protein, found to be molecular target for linaclotide which acts by activating GC-C receptor on the apical surface of intestinal epithelial cells. Binding of linaclotide to GC-C receptor triggers the elevation of second messenger cGMP that elicits fluid secretion into intestinal cells which play a critical role in maintaining homeostasis through cystic fibrosis transmembrane conductance regulator (CFTR). Data from Phase and clinical trials demonstrated that linaclotide seems to produce a statisticall significant increase in stool frequency, improved straining, decreased abdominal pain and discomfort.

Loading

Article metrics loading...

/content/journals/mrmc/10.2174/1389557511313110011
2013-10-01
2024-11-02
Loading full text...

Full text loading...

/content/journals/mrmc/10.2174/1389557511313110011
Loading
  • Article Type: Research Article
Keyword(s): cGMP; CIC; guanylate cyclase C; homeostasis; IBS-C; Linaclotide
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test